Due to the fact that its efficacies for PPARγ activation often match with those of pioglitazone (Figure 2A vs. Figure 2I, Figure 2B vs. Figure 2J, and Figure 3B vs. Figure 3F), PPARγ-related undesirable side effects (such as weight gain, edema, bone loss, and congestive heart failure) [42] should be closely monitored in the case of lanifibranor. This evidence concerns the gene PPARG and congestive heart failure.